Ehave's Mycotopia Therapies To Merge With Ei.Ventures To Form PSLY.COM
Ehave's Mycotopia Therapies To Merge With Ei.Ventures To Form PSLY.COM
Mycotopia Therapies (OTCPK:TPIA) subsidiary of Ehave, Inc. (OTCPK:EHVVF), has signed a definitive agreement to complete a triangular merger with Ei.Ventures, to form PSLY.COM. The companies anticipate closing the transaction on or about July 30, 2022.
真菌托邦療法 （OTCPK: TPIA） Ehave, Inc. 的子公司 （OTCPK: EHVVF），已經簽署了最終協議 同意完成與 Ei.Ventures 的三角合併，以形成 PSLY.COM。兩家公司預計將在2022年7月30日左右完成交易。
Ehave owns approximately 9.79 million shares of Mycotopia Therapies, which was valued around $28.4 million at the close on May 20. As of May 16, 2022 Ehave currently has 276.77 million shares outstanding, which values Ehave's stake in Mycotopia Therapies at more than $0.10 per share. In addition to Ehave's Mycotopia Therapies stake, the company owns its KetaDASH subsidiary, MetaHealthU, and is developing partnerships with SelfDecode, COGAPPS, GoMeyra, and Vastmindz.
Ehave擁有Mycotopia Therapis的約979萬股股份，截至5月20日收盤時，該股的價值約爲2,840萬美元。截至2022年5月16日，Ehave目前有2.7677億股已發行股票，這使Ehave在Mycotopia Therapis的股份估值超過每股0.10美元。除了 Ehave 的 Mycotopia Therapies 股份外，該公司還擁有其 KetaDash 子公司， MetaHealt，並正在與之建立夥伴關係 SelfDecode、COGAPPS、GoMeyra 和 Vastmindz。
The transaction between Mycotopia Therapies and Ei.Ventures will be structured as a triangular merger. The two companies will form a new holding company, PSLY.COM, and operate as subsidiaries after the merger. PSLY.COM will apply for a NASDAQ listing. Mycotopia Therapies primary focus is on mushroom and psychedelic opportunities. The company has been performing most of its research in Jamaica, where psilocybin is legal, as well as working with one of the largest cannabis labs in the Netherlands to develop psychedelics to jointly license certain molecules to be used in psychedelic medicine. Ei.Ventures' ambition is to deliver governmental approved therapeutic treatment options that address the current global mental healthcare pandemic. By leveraging blockchain, emerging technologies and the Metaverse, Ei.Ventures intends to create a safe, efficient, and secure way to provide telehealth services in general, as well as for psychoactive therapeutics.
Mycotopia Therapia Therapis和Ei.Ventures之間的交易將結構爲三角合併。 兩家公司將組建新的控股公司PSLY.COM，並在合併後作爲子公司運營。PSLY.COM將申請在納斯達克上市。 Mycotopia Therapias 的主要重點是蘑菇和迷幻的機會。 該公司的大部分研究都在牙買加進行，那裏的迷幻藥是合法的，並與荷蘭最大的大麻實驗室之一合作開發迷幻藥，以共同許可某些分子用於迷幻藥物。Ei.Ventures的目標是提供政府批准的治療方案，以應對當前的全球心理健康疫情。通過利用區塊鏈、新興技術和元宇宙，Ei.Ventures打算創造一種安全、高效和可靠的方式來提供一般的遠程醫療服務以及精神活性療法。
Ben Kaplan, CEO of Ehave, Inc., stated, "The statistics on the declining state of mental health in America are devastating. Globally, the statistics are even more bleak. Ei.Ventures recently completed a successful reg A offering, which raised over $25 million. Their plan is not only to profit from delivering governmental approved therapeutic treatment options that address the current global mental healthcare crisis, but to provide solutions for the millions of people who want to improve their mental health. Not only will this transaction afford Ei.Ventures with better opportunities to raise capital in order to execute its business plan, it is a fantastic opportunity to monetize Ehave's Mycotopia Therapies asset for our shareholders."
本·卡普蘭，Ehave, Inc. 首席執行官表示：“關於美國心理健康狀況下降的統計數據是毀滅性的。在全球範圍內，統計數據更加慘淡。Ei.Ventures最近成功完成了註冊A發行，籌集了超過2500萬美元的資金。他們的計劃不僅是通過提供政府批准的應對當前全球心理健康危機的治療方案中獲利，而且還要爲數百萬想要改善心理健康的人提供解決方案。這筆交易不僅將爲Ei.Ventures提供更好的籌集資金以執行其商業計劃的機會，而且也是爲我們的股東通過Ehave的Mycotopia Therapia Therapia資產獲利的絕佳機會。”
Photo: Courtesy of Marco Allegretti on Unsplash
照片：由 Unsplash 的 Marco Allegretti 提供
Related News
相關新聞
Psyched: Psilocybin Therapy Effective After One Year, Cybin & Deepak Chopra, Enveric Psilocybin Cancer Study
Psyched：Psilocybin 療法在一年後生效，Cybin & Deepak Chopra，Enveric Psilocybin 癌症研究
KetaDASH Announces Mobile Ketamine Treatments in San Francisco and Sacramento Area
KetaDash 宣佈在舊金山和薩克拉曼多地區進行****移動治療
譯文內容由第三人軟體翻譯。